PegBio (HKG:2565) is considering granting an exclusive license for Visepegenatide to UAE pharmaceutical R&D organization PDC FZ-LLC, a Friday Hong Kong bourse filing said.
Under the terms of the non-binding term sheet entered into between the parties, PDC will be granted a license to distribute, market, and commercialize the drug in the Middle East and Africa regions.
Visepegenatide is for the treatment of type II diabetes mellitus and obesity management, according to the biotechnology firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.